Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Fecha
2020-06-30Autor
García Marín, Jose Juan
Lamarca, Angela
Rodrigues, Pedro M.
Khan, Shahid A.
Roberts, Lewis R.
Cardinale, Vincenzo
Carpino, Guido
Andersen, Jesper B.
Braconi, Chiara
Calvisi, Diego
Perugorria Montiel, María Jesús
Fabris, Luca
Boulter, Luke
Macias, Rocio I. R.
Gaudio, Eugenio
Alvaro, Domenico
Gradilone, Sergio A.
Strazzabosco, Mario
Marzioni, Marco
Coulouarn, Cédric
Fouassier, Laura
Raggi, Chiara
Invernizzi, Pietro
Mertens, Joachim C.
Moncsek, Anja
Rizvi, Sumera
Heimbach, Julie
Groot Koerkamp, Bas
Bruix, Jordi
Forner, Alejandro
Bridgewater, John
Valle, Juan W.
Gores, Gregory J.
Metadatos
Mostrar el registro completo del ítem
Nature Reviews Gastroenterology & Hepatology 17(9) : 557–588 (2020)
Resumen
[EN] Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally,
currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies.
The silent presentation of these tumours combined with their highly aggressive nature and
refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all
cancer-related deaths worldwide yearly. The current diagnosis of CCA by non- invasive approaches
is not accurate enough, and histological confirmation is necessary. Furthermore, the high
heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises
the efficacy of the available therapies. In the past decade, increasing efforts have been made to
understand the complexity of these tumours and to develop new diagnostic tools and therapies
that might help to improve patient outcomes. In this expert Consensus Statement, which is
endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize
and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin,
genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments.
Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted
Excepto si se señala otra cosa, la licencia del ítem se describe como Copyright © 2020, Springer Nature This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.